Curcumin is Key to Unlocking Cancer Epigenetic Code - EuroPharma
Research at Baylor University shows curcumin awakens sleeping genes and reignites tumor suppression activity
GREEN BAY, Wis., June 23, 2011 /PRNewswire/ -- Dr. Ajay Goel, Ph.D., Director of Epigenetics and Cancer Prevention at the Gastrointestinal Research Center at Baylor University Medical Center in Dallas, TX, has announced plans for a series of upcoming studies to continue to unlock the mechanisms by which curcumin prevents cancer via its influence on epigenetic activity. While many people believe there is a strong genetic influence in the development of cancer, Dr. Goel states this is untrue. "Less that 5% of cancers arise from broken or damaged genes. The vast majority (more than 95%) are due to epigenetic influences. 'Epigenetics' is the study of the complex ways in which our genes are influenced by various dietary and environmental factors. Some factors turn genes on, and other factors subdue them or turn them off. This is good news. That means that you can influence 95% of all cancers with environment and lifestyle changes."
In a study published in the journal Gastroenterology, entitled "Novel Evidence for Curcumin-induced DNA Methylation Changes in Colon Cancer Cells,"(1) Dr. Goel examined epigenetic expression in colon cancer cells and the influence of curcumin on cancer prevention.
"It was a very technical study," reports Dr. Goel. "But in essence, we looked at a process in the body called methylation and how that process silences certain genes that are designed to suppress tumors. Curcumin was able to 'reawaken' the sleeping genes and reignite the body's own tumor suppression activity. This process keeps the cancerous tumor from growing and spreading, and is vitally important. Though we used colon cancer cells in this study, we suspect that this is one mechanism of action for cancer suppression in many other types of cancer as well. It is exciting new research and holds great promise for human health as the science continues to unfold. That is why our upcoming studies will continue to explore the epigenetic connection."
BCM-95® curcumin was used in this study. "I selected this form of curcumin because of its purity and lack of unfavorable solvents that can interfere with research results. This type of curcumin is of interest in human studies as well, because it has 7 to 10 times the absorption of plain curcumin, which means we can achieve more significant serum curcuminoid levels with fewer capsules for the study participant," states Dr. Goel.
EuroPharma, Inc. is the exclusive distributor of BCM-95® curcumin products in the U.S. through both the health food store and professional distribution channels. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. Terry Lemerond, founder and president of EuroPharma, is well-known for innovation, as he is credited as the first to introduce glucosamine sulfate, standardized Ginkgo biloba, and the award winning natural pain product, Curamin®, to the U.S. natural products market. At EuroPharma, Our Passion is Your Health™. For more information on EuroPharma, visit www.EuroPharmaUSA.com.
(1) A. Link, F. Balaguer, Y. Shen, J. Jose Lozano, HE. Leung, C.R. Boland, A. Goel. M1182 Novel Evidence for Curcumin-Induced DNA Methylation Changes in Colon Cancer Cells. Gastroenterology. May 2010 (Vol. 138, Issue 5, Supplement 1, Page S-349, DOI: 10.1016/S0016-5085(10)61608-3).
SOURCE EuroPharma, Inc.
CONTACT: Dean Draznin, +1-641-472-2257, mobile, +1-323-397-2647, email@example.com, or Diane Chojnowski, +1-641-209-9591, mobile, +1-641-919-0385, firstname.lastname@example.org, both of Dean Draznin Communications for EuroPharma, Inc.
Web Site: http://www.europharmausa.com
Posted: June 2011